MUSTANG BIO, INC. (MBIO)


Stock Price Forecast

April 22, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading MUSTANG BIO, INC. chart...

About the Company

Mustang Bio (Nasdaq: MBIO) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency (X-SCID).

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

114

Exchange

Nasdaq

$M

Total Revenue

114

Employees

$3M

Market Capitalization

-0.06

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MBIO News

Worcester biotech down to 11 employees after asset sale stalls

1d ago, source:

The company's recent struggles are tied in part to an ongoing federal government review of its deal to sell manufacturing ...

Mustang Bio (NASDAQ: MBIO)

4d ago, source: The Motley Fool

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers ...

Mustang Bio stock tumbles 27% amid news of mass layoffs

on MSN ago, source:

Mustang Bio (MBIO) stock tumbled 27% Monday in the wake of news that the company plans to cut around 81% of its workforce to ...

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

26d ago, source: Business Insider

March 28, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and ...

Mustang Bio to Cut Global Headcount by 81%

11d ago, source:

By Sabela Ojea Mustang Bio said is reducing its total workforce by about 81% to cut costs due to the current fundraising environment. The ...

MBIO Mustang Bio, Inc.

5d ago, source: Seeking Alpha

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors ...

Mustang Bio, Inc.: Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

26d ago, source: Finanznachrichten

March 28, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene ...

Mustang Bio Inc MBIO

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mustang Bio Inc MBIO

14d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mustang Bio Inc.

27d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...